Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 12/2009

01-12-2009 | Article

Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes

Authors: N. Tolonen, C. Forsblom, L. Thorn, J. Wadén, M. Rosengård-Bärlund, M. Saraheimo, M. Feodoroff, V.-P. Mäkinen, D. Gordin, M.-R. Taskinen, P.-H. Groop, FinnDiane Study Group

Published in: Diabetologia | Issue 12/2009

Login to get access

Abstract

Aims/hypothesis

We studied the impact of baseline lipid variables on the progression of renal disease in a large nationwide prospective cohort of patients with type 1 diabetes.

Methods

A total of 2,304 adult patients with type 1 diabetes and available lipid profiles participating in the Finnish Diabetic Nephropathy Study (FinnDiane) were evaluated. Data on progression of renal disease were verified from medical files and patients were followed for 5.4 ± 2.0 (mean ± SD) years.

Results

High triacylglycerol, apolipoprotein (Apo) B, ApoA-II and HDL3-cholesterol concentrations predicted incident microalbuminuria. Progression to macroalbuminuria was predicted by high triacylglycerol and ApoB. When AER was entered into the model, triacylglycerol was no longer an independent predictor, but when patients with normal AER and microalbuminuria at baseline were pooled, triacylglycerol, HbA1c, male sex and AER were all independent predictors of renal disease. High total cholesterol, LDL-cholesterol, non-HDL-cholesterol and triacylglycerol as well as low HDL-cholesterol, HDL2-cholesterol, ApoA-I and ApoA-II concentrations were predictive of progression to end-stage renal disease. However, when estimated GFR was entered into the model, only total cholesterol remained an independent predictor of progression.

Conclusions/interpretation

Lipid abnormalities, particularly high triacylglycerol concentrations, increase the risk of progression of renal disease.
Appendix
Available only for authorised users
Literature
1.
Laing SP, Swerdlow AJ, Slater SD et al (1999) The British Diabetic Association cohort study, II: cause-specific mortality in patients with insulin-treated diabetes mellitus. Diabet Med 16:466–471CrossRefPubMed
2.
Tuomilehto J, Borch-Johnsen K, Molarius A et al (1998) Incidence of cardiovascular disease in type 1 (insulin-dependent) diabetic subjects with and without diabetic nephropathy in Finland. Diabetologia 41:784–790CrossRefPubMed
3.
The Diabetes Control and Complications (DCCT) Research Group (1995) Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 47:1703–1720CrossRef
4.
5.
Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T (1983) Diabetic nephropathy in type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia 25:496–501CrossRefPubMed
6.
Sawicki PT, Didjurgeit U, Muhlhauser I, Bender R, Heinemann L, Berger M (1994) Smoking is associated with progression of diabetic nephropathy. Diabetes Care 17:126–131CrossRefPubMed
7.
Mulec H, Johnsen SA, Wiklund O, Bjorck S (1993) Cholesterol: a renal risk factor in diabetic nephropathy? Am J Kidney Dis 22:196–201PubMed
8.
Tolonen N, Forsblom C, Thorn L, FinnDiane Study Group et al (2008) Relationship between lipid profiles and kidney function in patients with type 1 diabetes. Diabetologia 51:12–20CrossRefPubMed
9.
Groop PH, Elliott T, Ekstrand A et al (1996) Multiple lipoprotein abnormalities in type I diabetic patients with renal disease. Diabetes 45:974–979CrossRefPubMed
10.
Thomas MC, Rosengard-Barlund M, Mills V et al (2006) Serum lipids and the progression of nephropathy in type 1 diabetes. Diabetes Care 29:317–322CrossRefPubMed
11.
Hadjadj S, Duly-Bouhanick B, Bekherraz A et al (2004) Serum triglycerides are a predictive factor for the development and the progression of renal and retinal complications in patients with type 1 diabetes. Diabetes Metab 30:43–51CrossRefPubMed
12.
Shepherd J, Kastelein JJ, Bittner V, Treating to New Targets, Investigators et al (2007) Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: The treating to new targets (TNT) study. Clin J Am Soc Nephrol 2:1131–1139CrossRefPubMed
13.
Atthobari J, Brantsma AH, Gansevoort RT, PREVEND Study Group et al (2006) The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. Nephrol Dial Transplant 21:3106–3114CrossRefPubMed
14.
Sandhu S, Wiebe N, Fried LF, Tonelli M (2006) Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 17:2006–2016CrossRefPubMed
15.
Coonrod BA, Ellis D, Becker DJ et al (1993) Predictors of microalbuminuria in individuals with IDDM. Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 16:1376–1383CrossRefPubMed
16.
Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH (2001) Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int 60:219–227CrossRefPubMed
17.
Giorgino F, Laviola L, Cavallo Perin P, Solnica B, Fuller J, Chaturvedi N (2004) Factors associated with progression to macroalbuminuria in microalbuminuric type 1 diabetic patients: the EURODIAB Prospective Complications Study. Diabetologia 47:1020–1028CrossRefPubMed
18.
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 130:461–470PubMed
19.
Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41CrossRefPubMed
20.
James RW, Pometta D (1990) Immunofractionation of high density lipoprotein subclasses 2 and 3 similarities and differences of fractions isolated from male and female populations. Atherosclerosis 83:35–45CrossRefPubMed
21.
Sweetnam PM, Bolton CH, Downs LG et al (2000) Apolipoproteins A-I, A-II and B, lipoprotein(a) and the risk of ischaemic heart disease: The Caerphilly Study. Eur J Clin Invest 30:947–956CrossRefPubMed
22.
O’Brien T, Nguyen TT, Hallaway BJ et al (1995) The role of lipoprotein A-I and lipoprotein A-I/A-II in predicting coronary artery disease. Arterioscler Thromb Vasc Biol 15:228–231PubMed
23.
Birjmohun RS, Dallinga-Thie GM, Kuivenhoven JA et al (2007) Apolipoprotein A-II is inversely associated with risk of future coronary artery disease. Circulation 116:2029–2035CrossRefPubMed
24.
Barter PJ, Rye KA (1996) High density lipoproteins and coronary heart disease. Atherosclerosis 121:1–12CrossRefPubMed
25.
Alaupovic P, Mack WJ, Knight-Gibson C, Hodis HN (1997) The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol 17:715–722PubMed
26.
Groop PH, Thomas MC, Rosengard-Barlund M et al (2007) HDL composition predicts new-onset cardiovascular disease in patients with type 1 diabetes. Diabetes Care 30:2706–2707CrossRefPubMed
27.
Hopkins GJ, Barter PJ (1986) Role of triglyceride-rich lipoproteins and hepatic lipase in determining the particle size and composition of high density lipoproteins. J Lipid Res 27:1265–1277PubMed
28.
Orchard TJ, Chang YF, Ferrell RE, Petro N, Ellis DE (2002) Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study. Kidney Int 62:963–970CrossRefPubMed
29.
Thorn LM, Forsblom C, Waden J, on behalf of the FinnDiane Study Group et al (2009) he metabolic syndrome as a risk factor for cardiovascular disease, mortality, and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care 32:950–952CrossRefPubMed
30.
Colhoun HM, Lee ET, Bennett PH et al (2001) Risk factors for renal failure: the WHO multinational study of vascular disease in diabetes. Diabetologia 44:S46–S53CrossRefPubMed
31.
Sniderman AD, Pedersen T, Kjekshus J et al (1997) Putting low-density lipoproteins at center stage in atherogenesis. Am J Cardiol 79:64–67CrossRefPubMed
32.
Durrington PN, Bolton CH, Hartog M et al (1978) Serum and lipoprotein apolipoprotein B levels in normal subjects and patients with hyperlipoproteinaemia. Clin Chim Acta 82:151–160CrossRefPubMed
33.
Westerveld HT, van Lennep JE, van Lennep HW et al (1998) Apolipoprotein B and coronary artery disease in women: a cross-sectional study in women undergoing their first coronary angiography. Arterioscler Thromb Vasc Biol 18:1101–1107PubMed
34.
Yishak AA, Costacou T, Virella G et al (2006) Novel predictors of overt nephropathy in subjects with type 1 diabetes. A nested case control study from the Pittsburgh epidemiology of diabetes complications cohort. Nephrol Dial Transplant 21:93–100CrossRefPubMed
35.
DCCT Research Group (1992) Lipid and lipoprotein levels in patients with IDDM diabetes control and complication. Trial experience. Diabetes Care 15:886–894CrossRef
36.
de Boer IH, Astor BC, Kramer H et al (2008) Lipoprotein abnormalities associated with mild impairment of kidney function in the multi-ethnic study of atherosclerosis. Clin J Am Soc Nephrol 3:125–132CrossRefPubMed
37.
38.
Niemi J, Mäkinen V-P, Heikkonen J et al (2009) Estimation of VLDL, IDL, LDL, HDL(2), apoA-I and apoB from the Fiedewald inputs—apoB and IDL, but not LDL, are associated with mortality in type 1 diabetes. Ann Med. doi:10.​1080/​0785389090289339​2 PubMed
39.
Miller M, Ginsberg HN, Schaefer EJ (2008) Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease. Am J Cardiol 101:1003–1008CrossRefPubMed
40.
Kastelein JJ, van der Steeg WA, Holme I, TNT Study Group, IDEAL Study Group et al (2008) Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 117:3002–3009CrossRefPubMed
Metadata
Title
Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes
Authors
N. Tolonen
C. Forsblom
L. Thorn
J. Wadén
M. Rosengård-Bärlund
M. Saraheimo
M. Feodoroff
V.-P. Mäkinen
D. Gordin
M.-R. Taskinen
P.-H. Groop
FinnDiane Study Group
Publication date
01-12-2009
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 12/2009
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1541-2

Other articles of this Issue 12/2009

Diabetologia 12/2009 Go to the issue

Research Letter

Insulin pump failures are still frequent: a prospective study over 6 years from 2001 to 2007

Letter

Increased insulin dose requirement of long-acting insulin analogues in obese patients with type 2 diabetes

Commentary

Cognitive decline associated with dementia and type 2 diabetes: the interplay of risk factors

Short Communication

Diverse roles for protein kinase C δ and protein kinase C ε in the generation of high-fat-diet-induced glucose intolerance in mice: regulation of lipogenesis by protein kinase C δ

Article

Neural crest stem cells increase beta cell proliferation and improve islet function in co-transplanted murine pancreatic islets

Short Communication

Heritability and genetic correlations of insulin resistance and component phenotypes in Asian Indian families using a multivariate analysis
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits